To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Males or females aged 35 to 75. * Type 2 diabetes mellitus (DM) patients coupled with hypertension \[sitting systolic blood pressure (SSBP) 140-179 mm Hg and/or SDBP 90-109 mm Hg\]. * Urinary albumin creatinine Ratio (UACR)) indicating microalbuminuria/proteinuria \[30-1000 mg/g or 2.5-25 mg/mmol\] * Body mass index (BMI) \<40 kg/m2 * Patients who will sign an informed consent. Exclusion Criteria * Type 1 DM * All causes of secondary diabetes mellitus * Women of childbearing potential who refuse to use contraception. * Pregnant or lactating females. * Severe hypertension \[SSBP\> 180 mmHg, sitting diastolic blood pressure (SDBP) \> 110 mmHg \] * Patients who are on combo therapy to control BP * Patients who are already on Valsartan. * Hypersensitivity to Valsartan. * Renal artery stenosis \[ unilateral or bilateral\] * Patients taking β blockers, (Angiotensin Converting Enzyme Inhibitor (ACEI) or spironolactone * Heart Failure * History of myocardial infarction, Percutaneous Transluminal Coronary Angioplasty(PTCA) or cerebrovascular accident within the preceding 3 months. * Creatinine levels \> 1.4 mg/dl \[ 0.07mmol/l\]. Liver enzymes \> 2 times Upper Limit of the Normal Range(ULN). Diabetic keto-acidosis (DKA) within the last 6 months. Presence of diabetic neuropathy or retinopathy. Diabetic foot complications. Presence of infection at time of screening. Hyperkalemia (serum K+ \> 5.5 mmol/L)